Literature DB >> 19877740

Anidulafungin, a new echinocandin: in vitro activity.

Giulia Morace1, Elisa Borghi, Roberta Iatta, Maria Teresa Montagna.   

Abstract

Anidulafungin is an antifungal drug belonging to the echinocandin class with a potent in vitro fungicidal activity against a wide range of Candida species, including C. glabrata and C. krusei. Anidulafungin is also active in vitro against moulds belonging to the genus Aspergillus and some dematiaceous genera. Furthermore, anidulafungin demonstrates in vitro activity against Candida spp. growing as biofilms. Resistance to anidulafungin remains very rare based on recent epidemiological data. Paradoxical or trailing effects should be considered in echinocandin susceptibility testing. The in vitro activity profile of anidulafungin makes it a useful addition to the Italian antifungal armamentarium.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19877740     DOI: 10.2165/11315560-000000000-00000

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  12 in total

Review 1.  Anidulafungin: a new echinocandin for the treatment of fungal infections.

Authors:  Michael Cohen-Wolkowiez; Daniel K Benjamin; William J Steinbach; P Brian Smith
Journal:  Drugs Today (Barc)       Date:  2006-08       Impact factor: 2.245

2.  Differential activities of newer antifungal agents against Candida albicans and Candida parapsilosis biofilms.

Authors:  Aspasia Katragkou; Athanasios Chatzimoschou; Maria Simitsopoulou; Maria Dalakiouridou; Eudoxia Diza-Mataftsi; Chaido Tsantali; Emmanuel Roilides
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191

3.  Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints.

Authors:  M A Pfaller; D J Diekema; L Ostrosky-Zeichner; J H Rex; B D Alexander; D Andes; S D Brown; V Chaturvedi; M A Ghannoum; C C Knapp; D J Sheehan; T J Walsh
Journal:  J Clin Microbiol       Date:  2008-06-25       Impact factor: 5.948

4.  In vitro activity of anidulafungin against Candida albicans biofilms.

Authors:  Melissa J Jacobson; Kerryl E Piper; Gary Nguyen; James M Steckelberg; Robin Patel
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

5.  In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.

Authors:  M A Pfaller; L Boyken; R J Hollis; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

6.  In vitro susceptibilities of invasive isolates of Candida species: rapid increase in rates of fluconazole susceptible-dose dependent Candida glabrata isolates.

Authors:  Sheng-Yuan Ruan; Chen-Chen Chu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

7.  Paradoxical effect of caspofungin: reduced activity against Candida albicans at high drug concentrations.

Authors:  David A Stevens; Marife Espiritu; Rachana Parmar
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

8.  Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.

Authors:  M A Ghannoum; A Chen; M Buhari; J Chandra; P K Mukherjee; D Baxa; A Golembieski; J A Vazquez
Journal:  Clin Microbiol Infect       Date:  2009-02-05       Impact factor: 8.067

9.  In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2007-11-21       Impact factor: 5.948

10.  Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.

Authors:  M Fleischhacker; C Radecke; B Schulz; M Ruhnke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-04       Impact factor: 3.267

View more
  3 in total

1.  Conclusions. Anidulafungin is a new echinocandin developed for more effective treatment of serious systemic fungal infections.

Authors:  Pasquale De Bellis
Journal:  Drugs       Date:  2009       Impact factor: 9.546

2.  Activities of fluconazole, caspofungin, anidulafungin, and amphotericin B on planktonic and biofilm Candida species determined by microcalorimetry.

Authors:  Elena Maryka Maiolo; Ulrika Furustrand Tafin; Olivier Borens; Andrej Trampuz
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

3.  Effect of reduced oxygen on the antifungal susceptibility of clinically relevant aspergilli.

Authors:  Ulrike Binder; Elisabeth Maurer; Michaela Lackner; Cornelia Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.